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Background. There is currently an experts’ agreement discouraging interruption of antiretroviral treatment
(ART) during the first trimester of pregnancy in women infected with human immunodeficiency virus type 1
(HIV-1). However, this recommendation is poorly supported by data. We evaluated the effects of discontinuing
ART during pregnancy on the rate of mother-to-child transmission.
Methods. Logistic regression models were performed in a prospective cohort of 937 children who were per-
inatally exposed to HIV-1 to estimate adjusted odds ratios for confounding factors on mother-to-child transmission,
including maternal interruption of ART.
Results. Among 937 pregnant women infected with HIV-1, ART was interrupted in 81 (8.6%) in the first
trimester and in 11 (1.2%) in the third trimester. In the first trimester, the median time at suspension of ART
was 6 weeks (interquartile range [IQR], 5–6 weeks) and the time without treatment was 8 weeks (IQR, 7–11
weeks). In the third trimester, the median time at suspension of ART was 32 weeks (IQR, 23–36 weeks) and the
time without treatment was 6 weeks (IQR, 2–9 weeks). The plasma viral load was similar in women who had
treatment interrupted in the first trimester and in those who did not have treatment interrupted.
Overall, the rate of mother-to-child transmission in the whole cohort was 1.3% (95% confidence interval [CI],
0.7%–2.3%), whereas it was 4.9% (95% CI, 1.9%–13.2%) when ART was interrupted in the first trimester and
18.2% (95% CI, 4.5%–72.7%) when ART was interrupted in the third trimester. In the multiple logistic regression
models, only interruption of ART during either the first or the third trimester, maternal mono- or double therapy,
delivery by a mode other than elective cesarean delivery, and a viral load at delivery 14.78 log10 copies/mL were
independently associated with an increased rate of mother-to-child transmission.
Conclusions. Discontinuing ART during pregnancy increases the rate of mother-to-child transmission of HIV-
1, either when ART is stopped in the first trimester and subsequently restarted or when it is interrupted in the
third trimester. This finding supports recommendations to continue ART in pregnant women who are already
receiving treatment for their health.
After the results of the Pediatric AIDS Clinical Trials
Group Protocol 076 Study Group [1], several prospec-
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tive studies have confirmed the effectiveness of anti-
retroviral treatment (ART) during pregnancy in de-
creasing the rate of mother-to-child transmission
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(MTCT) of HIV-1 [2–5]. In developed countries, the synergic
effect of ART in the mother and newborn, cesarean delivery,
and avoidance of breast-feeding have resulted in a rate of MTCT
of !2% [2–5]. In the HAART era, the rate of MTCT is ∼1%,
probably because of the strong effect of HAART on the maternal
viral load [6]. Therefore, there is a consensus on the benefits
of HAART for the mother’s health and for prevention of MTCT,
provided that drugs with a potential toxicity for the offspring
are avoided [7]. Data from prospective registries [8] support
lack of teratogenicity with exposure to antiretroviral drugs dur-
ing pregnancy, but with the increasing use of new molecules,
monitoring of birth defects is continually needed. An increasing
number of treated women are now identified as pregnant, and
presently there is an experts’ opinion discouraging a temporary
discontinuation of ART during the first trimester [7]. However,
this opinion is only partially supported by evidence. To date,
insufficient data support an increase in the rate of MTCT as a
consequence of ART discontinuation during pregnancy. We
performed an analysis involving a large cohort of children pro-
spectively enrolled in the Italian Register for HIV Infection in
Children, to evaluate the effect of discontinuation of ART dur-
ing pregnancy on the rate of MTCT.
METHODS
Data collection. The Italian Register for HIV Infection in
Children is a nationwide multicenter study of children peri-
natally exposed to HIV-1 that was instituted in 1985. Data come
from a network of 106 participating pediatric centers located
throughout Italy, representing the overall population of exposed
infants in Italy [3]. Informed consent at the local pediatric
center and National Privacy Agency permission are obtained.
Both at-risk children identified at birth and infected children
identified after birth are enrolled. In this study, only exposed
children identified at birth who were born to treated mothers
and who had known infectious status were considered [3]. Data
with regard to mother-infant pairs were collected as described
elsewhere [3, 9]. Detailed data on the type of regimen(s), ges-
tational age at beginning and end of ART (for each single
regimen if switches occurred during pregnancy), and ART ad-
ministered intrapartum and/or to the newborn were included.
Maternal data were obtained at each pediatric center from an
infectious diseases report and/or a gynecologist’s report, and
they were recorded at the infant’s first examination, at birth.
From 2001, information on the maternal plasma viral RNA
load and CD4+ cell counts at the time of delivery and infor-
mation on the last antiretroviral regimen (the type and the date
of initiation) prior to pregnancy were collected. Because this
information was uniformly available only since 2002, only chil-
dren born in 2002 or later were evaluated in the present study.
Viral loads and CD4+ cell counts were evaluated as described
elsewhere [3, 9]. Both baseline and follow-up information on
the infant’s infection status, HIV-1 antibodies, and viral mark-
ers (HIV-1 DNA or RNA detection) were collected [3].
Case definition. Infection in children [3, 9, 10], elective
cesarean delivery [2], and duration of ART during pregnancy
[9] were defined as reported. To evaluate the effect of type of
ART on the rate of MTCT, we defined monotherapy as zido-
vudine (according to the Pediatric AIDS Clinical Trials Group
Protocol 076 Study Group protocol), double therapy as any
regimen including 2 nucleoside reverse-transcriptase inhibitors
(NRTI), and HAART as any combination regimen with 3
antiretroviral drugs (no mother received a triple NRTI regi-
men). Among HAART regimens, a nevirapine-based regimen
was defined as any triple regimen including 2 NRTIs plus ne-
virapine, and a protease inhibitor (PI)–based regimen was de-
fined as any triple (or more) regimen including NRTIs plus a
PI. When 11 regimen was received during pregnancy, the more
complex (i.e., HAART vs. double) was considered. Maternal
interruption of ART was defined as the discontinuation of any
ART for 115 days. Shorter periods of interruption, in fact, could
not be reported by the mothers. Moreover, it is usually believed
that plasma viral RNA load significantly decreases after 2 weeks
of treatment, and perinatal guidelines recommend monitoring
maternal viral load 2–6 weeks after initiating or changing ART
[7]. The gestational age at ART initiation was defined as the
week at the beginning of the first ART regimen for women
who did not receive therapy during the periconceptional period.
Statistical analysis. Analyses were performed on data re-
ported through December 2005 for children followed up since
birth who were born from 1 January 2002 through 31 December
2004. Children born from 1 January 2005 through 30 June
2005 were excluded from analysis because of the large per-
centage of exposed children with an undetermined HIV-1
status.
Data were expressed as median and interquartile range (IQR)
or as mean and 95% CI. Differences in proportions were eval-
uated by the x2 test. A nonparametric 3-sample test was per-
formed to test the hypothesis of median equality. The analysis
of variance was used to test for differences in maternal viral
load at delivery. To evaluate the association of ART interruption
with the rate of MTCT, logistic regression models were per-
formed to estimate adjusted ORs for factors potentially influ-
encing the rate of MTCT: infant’s sex, gestational age (!37
weeks, 37 weeks, or unknown), plasma viral RNA load at
delivery (!2.6, 2.6–4.00, 4.01–5.78, 15.78 log10 copies/mL, or
unknown), CD4+ cell count at delivery (!200, 200–499, 500
cells/mL, or unknown), mode of delivery (vaginal delivery, elec-
tive cesarean delivery, cesarean delivery other than elective, or
unknown), maternal ART in pregnancy (zidovudine mono-
therapy, double therapy, HAART, or unknown), maternal in-
terruption of ART (yes or no), intrapartum ART (yes, no, or
unknown), and neonatal ART (yes, no, or unknown). Because
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Table 1. Characteristics of 937 mother-child pairs in
our study of mother-to-child transmission of HIV-1
infection.
Variable
No. (%) of
mother-child pairs
Mother
Type of ART
Monotherapy 99 (10.6)
Double therapy 187 (20.0)
HAART 651 (69.5)
Type of ART before interruption (n p 81)
Nevirapine-based HAART 27 (33.3)
Protease inhibitor-based HAART 27 (33.3)
Other regimen of HAART 19 (23.5)
Nonspecified HAART 2 (2.5)
Double therapy 3 (3.7)
Monotherapy 3 (3.7)
Type of ART after interruption (n p 81)
Nevirapine-based HAART 33 (40.7)
Protease inhibitor–based HAART 33 (40.7)
Other regimen of HAART 6 (7.4)
Nonspecified HAART 2 (2.5)
Double therapy 3 (3.7)
Monotherapy 4 (4.9)
Type of delivery
Elective cesarean 860 (91.8)
Cesarean other than elective 51 (5.4)
Vaginal 20 (2.1)
Unknown 6 (0.6)
Viral load at delivery, log10 copies/mL
!2.6 453 (48.3)
2.6–4.00 133 (14.2)
4.01–4.78 C36 (3.8)
14.78 8 (0.9)
Unknown 307 (32.8)
CD4+ cell count at delivery, cells/mL
!200 43 (4.6)
200–499 267 (28.5)
500 265 (28.3)
Unknown 362 (38.6)
Intrapartum ART
Yes 847 (90.4)
No 90 (9.6)
Child
Sex
Male 482 (51.4)
Female 455 (48.6)
Gestational age
!37 weeks 187 (20.0)
37 weeks 745 (79.5)
Unknown 5 (0.5)
Neonatal ART
Yes 915 (97.7)
No 22 (2.3)
Infectious status
Infected 12 (1.3)
Uninfected 925 (98.7)
NOTE. HAART was defined as 3 antiretroviral drugs. ART,
antiretroviral therapy.
no child was breast-fed, the mode of feeding was not included
in the regression analyses. To better evaluate interaction be-
tween quantitative variables potentially associated with the rate
of MTCT, an additional logistic regression model with log10
plasma viral RNA load and log10 CD4
+ cell count as continuous
variables was performed for a subgroup of mother-child pairs
with both variables known.
RESULTS
Mother-infant pairs. Overall, 937 of 1016 mother-child pairs
receiving ART entered the study; 79 (7.8%) of the exposed
infants were excluded because they were lost to follow-up before
ascertainment of infectious status. The characteristics of the
937 mothers and children are shown in table 1. Intrapartum
and neonatal prophylaxis consisted of zidovudine in all but 8
cases in which nevirapine was given. Maternal plasma viral load
was known in 630 (67.2%) of the 937 mother-child pairs. Of
the 630 women with known viral load, the majority (453
[71.9%]) showed an undetectable plasma viral load (tested by
an assay with a cutoff value of 50 copies/mL [ ] andnp 340
400 copies/mL [ ]). Characteristics of mother-childnp 113
pairs were compared according to known or unknown maternal
plasma viral load. Frequency of intrapartum ART administra-
tion was higher when maternal viral load was known (586
[93.0% ] of 630 women vs. 261 [85.0%] of 307 women; x2 p
15.21.5; ), and frequency of prepartum HAART ad-P ! .001
ministration was higher when maternal viral load was known
(454 [72.1%] of 630 women vs. 197 [64.2%] of 307 women;
x2 p 6.07; ); no difference was observed in the fre-Pp .014
quency of mode of elective cesarean delivery (580 [92.1%] of
630 women vs. 280 [91.2%] of 307 women; x2 p 0.20; Pp
), the use of neonatal ART (614 [97.5%] of 630 infants vs..653
301 [98.0%] of 307 infants; x2 p 0.31; ), and thePp .579
infant’s infectious status (8 [1.3%] of 630 cases vs. 4 [1.3%]
of 307 cases; x2 p 0.002; ). The maternal viral loadPp .966
decreased as the complexity of the ART regimen increased. The
mean plasma viral load was 2.6 log10 copies/mL (95% CI, 2.2–
2.9 log10 copies/mL), 2.4 log10 copies/mL (95% CI, 2.2–2.6 log10
copies/mL), and 1.9 log10 copies/mL (95% CI, 1.8–2.0 log10
copies/mL) in women receiving monotherapy, double therapy,
or HAART, respectively (analysis of variance, ;Fp 17.2 P !
). The median gestational age at the beginning of treatment.001
was 18 weeks (IQR, 13–35 weeks), 18 weeks (IQR, 13–25
weeks), and 13 weeks (IQR, 6–22 weeks) in women receiving
monotherapy, double therapy, or HAART, respectively, thus
decreasing with the increase in the ART complexity (x2p 36.8;
). The proportion of women with detectable viral loadP ! .001
did not differ according to trimester at start of ART when
monotherapy was given ( ; 78.6% during the first tri-np 50
mester, 55.0% during the second trimester, and 56.3% during
the third trimester; x2 p 2.27; ) In addition, the pro-Pp .321
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Table 2. Characteristics of the 12 mother-child pairs in which the infants were infected.
Identifier
Maternal ART regimen Interruption of ART Maternal
HIV-1
RNA load
at deliv-
ery, cop-
ies/mL
CD4+ cell
count at
delivery,
cells/mL
Gestational
age,
weeks
Intrapartum
ART
Neonatal
ART
At beginning of
pregnancy After interruption
After
switching
without
interruption
During
first
trimester
During
third
trimester
1 ddI+TDF+T20 ddI+TDF+NFV … Yes No 28,110 74 33 Yes Yes
2 ddI+d4T+LPV/RIT … AZT No No Unknown Unknown Unknown Yes Yes
3 AZT+3TC+NVP AZT+3TC+NVP … Yes No 780 781 38 Yes Yes
4 AZT+3TC+NFV … … No No 1710 839 38 Yes Yes
5 AZT … … No No Unknown Unknown 31 No Yes
6 d4T+TDF+LPV/RIT AZT+3TC+NVP … Yes No !50 326 27 No Yes
7 d4T+3TC+NFV d4T+3TC+NFV … No Yes 600,000 410 31 Yes Yes
8 AZT+ 3TC AZT + 3TC … Yes No 500,000 200 37 Yes No
9 AZT+3TC+NVP … … No No 16,900 468 39 Yes Yes
10 AZT+3TC … … No No 54 390 38 Yes Yes
11 AZT+3TC+NVP AZT+3TC+NVP … No Yes Unknown Unknown 21 Yes Yes
12 AZT … … No No 2800 141 Yes Yes
NOTE. All deliveries were elective cesarean deliveries. AZT, zidovudine; ddI, didanosine; d4T, stavudine; LPV/RIT, lopinavir-ritonavir; NFV, nelfinavir; NVP,
nevirapine; TDF, tenofovir; T20, enfuvirtide; 3TC, lamivudine.
portion of women with detectable viral load did not differ
according to the trimester during which ART was initiated when
double therapy was given ( ; 38.1% during the firstnp 126
trimester, 37.3% during the second trimester, and 47.1% during
the third trimester; x2 p 0.56; ). However, the pro-Pp .756
portion of women with detectable viral load was significantly
higher when HAART (given to 454 women) was started during
the third trimester (45.9%), compared with during the second
(17.5%) or first trimester (17.8%; x2 p 25.81; ).P ! .001
Women treated with HAART who had a known plasma viral
load had similar mean plasma viral loads when 281 women
who were treated with a PI-based regimen (1.95 log10 copies/
mL; 95% CI, 1.77–2.07 log10 copies/mL) were compared with
328 women treated with a nevirapine-based regimen (1.85 log10
copies/mL; 95% CI, 1.65–1.92 log10 copies/mL; Student’s t test,
1.29; ).Pp .197
Discontinuation and subsequent restart of ART was reported
in 81 (8.6%) of the 937 mother-child pairs in the first trimester
of pregnancy (median time at suspension, 6 weeks [IQR, 5–6
weeks]; median time without treatment, 8 weeks [IQR, 7–11
weeks]) and in 11 (1.2%) of the mother-child pairs in the third
trimester (median time at suspension, 32 weeks [IQR, 23–36
weeks]; median time without treatment, 6 weeks [IQR, 2–9
weeks]). Only 1 mother, who gave birth to an uninfected child,
had treatment interrupted during both the first and the third
trimesters. ART was more frequently interrupted at the begin-
ning of pregnancy in women treated with HAART (74 [11.4%]
of 651 women) than in women treated with double therapy (3
[1.6%] of 187 women) or with monotherapy (4 [4.0%] of 99
women; x2 test, 20.50; ).P ! .001
We checked whether women switched therapy after inter-
ruption to a less or more active regimen, but the proportions
of women treated with a nevirapine- or PI-based HAART reg-
imen before or after treatment interruption were similar (table
1). Treatment was restarted with the same class of antiretroviral
drugs in 47 (58.0%) of the 81 women, among whom 19 (23.5%)
received the same nevirapine-based regimen that they received
prior to the interruption.
Among women whose viral load at delivery was known, the
mean plasma viral load was similar in those who had treatment
interrupted in the first trimester (2.04 log10 copies/mL; 95%
CI, 1.81–2.26 log10 copies/mL) and in those who did not have
treatment interrupted (2.04 log10 copies/mL; 95% CI, 1.95–2.14
log10 copies/mL; Student’s t test, 0.04; ). Similarly,Pp .967
the mean CD4+ cell count at delivery was similar in women
who had treatment interrupted (2.63 log10 cells/mL; 95% CI,
2.57–2.69 log10 cells/mL) and in those who did not have treat-
ment interrupted (2.65 log10 cells/mL; 95% CI, 2.65–2.67 log10
cells/mL; Student’s t test, 0.40; ). Among HAART-Pp .689
treated women who had therapy interrupted and who had
known plasma viral load, we found no difference in mean
plasma viral load between 29 women treated with a PI-based
regimen (2.06 log10 copies/mL; 95% CI, 1.70–2.42 log10 copies/
mL) and 28 women treated with a nevirapine-based regimen
(1.85 log10 copies/mL; 95% CI, 1.69–2.01 log10 copies/mL; Stu-
dent’s t test, 1.12; ).Pp .268
MTCT rate and confounding factors. Overall, the rate of
MTCT in the whole cohort was 1.3% (95% CI, 0.7%–2.3%).
The rate of MTCT among children born to mothers who had
ART interrupted in the first trimester was 4.9% (95% CI, 1.9%–
13.2%), and the rate of MTCT among children born to mothers
who had ART interrupted in the third trimester was 18.2%
(95% CI, 4.5%–72.7%). Characteristics of the 12 mother-child
pairs in which the children were infected are shown in table 2.
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Table 3. Univariate and logistic regression analysis of risk factors for mother-to-child transmission
of HIV-1 infection.
Factor
No. of
infected
infants/total
no. of infants
Univariate analysis Multivariate analysis
OR (95% CI) P Adjusted OR (95% CI) P
Type of maternal ART
Monotherapy 5/99 Reference Reference
Double 1/187 0.10 (0.01–0.88) .038 0.21 (0.02–2.21) .192
HAART 6/651 0.18 (0.05–0.58) .005 0.17 (0.04–0.80) .025
Trimester at start of ART
First 5/463 Reference Reference
Second 4/321 1.16 (0.31–4.34) .830 0.54 (0.10–3.06) .487
Third 3/149 1.88 (0.44–7.97) .391 0.92 (0.15–5.51) .929
Unknown 0/4 NA NA
Interruption of ART
During the first trimester
No 8/856 Reference Reference
Yes 4/81 5.51 (1.62–18.70) .006 10.33 (2.02–52.91) .005
During the third trimester
No 10/926 Reference Reference
Yes 2/11 20.36 (3.89–106.42) !.001 46.86 (4.28–512.64) .002
Type of delivery
Elective cesarean 10/860 Reference Reference
Cesarean other than elective 2/51 3.47 (0.74–16.27) .115 5.9 (0.93–37.28) .059
Vaginal 0/20 NA NA
Unknown 0/6 NA NA
Viral load at delivery, log 10 copies/mL
!2.6 2/453 Reference Reference
2.61–4.00 3/133 5.20 (0.86–31.48) .073 4.78 (0.65–34.98) .124
4.01–4.78 1/36 6.44 (0.57–72.82) .132 7.41 (0.52–105.87) .140
14.78 2/8 75.17 (9.03–625.60) !.001 29.19 (1.80–473.81) .018
Unknown 4/307 2.98 (0.54–16.35) .210 7.69 (0.64–92.97) .109
CD4+ cell count at delivery, cells/mL
!200 1/43 Reference Reference
200–499 5/267 0.80 (0.09–7.03) .842 0.99 (0.09–11.09) .994
500 2/265 0.32 (0.03–3.60) .356 0.88 (0.06–12.59) .923
Unknown 4/362 0.47 (0.05–4.30) .503 0.25 (0.01–4.44) .341
Sex of child
Female 5/455 Reference Reference
Male 7/482 1.33 (0.42–4.21) .632 1.02 (0.25–4.13) .983
Intrapartum ART
No 2/90 Reference Reference
Yes 10/847 0.53 (0.11–2.44) .411 0.53 (0.09–3.11) .481
Neonatal ART
No 1/22 Reference Reference
Yes 11/915 0.26 (0.03–2.07) .201 0.84 (0.04–18.30) .912
NOTE. HAART was defined as 3 antiretroviral drugs. ART, antiretroviral treatment; NA, not applicable.
To evaluate the role of different risk factors for MTCT, uni-
variate and multiple logistic regression models were performed.
Maternal monotherapy or double therapy, interruption of ART
during either the first or the third trimester, delivery by a mode
other than elective cesarean delivery, and a viral load at delivery
14.78 log10 copies/mL were associated with an increased rate
of MTCT (table 3). Plasma viral load 14.78 log10 copies/mL
was associated with a 30-fold increased risk of transmission.
Other factors (maternal CD4+ cell count at delivery, trimester
at the start of ART, child’s sex, and intrapartum and neonatal
ART) were not significantly associated with the rate of MTCT.
When we included in an additional model the 79 exposed
infants lost to follow-up, with the assumption that all these
children were uninfected, results were unchanged (adjusted OR
for treatment interruption in the first trimester, 11.4; in the
third trimester, 34.1). The probability of infection in children
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in this group was very low, because missing infected children
are regained by periodical cross-matches with the Italian Na-
tional AIDS Registry, to which all AIDS cases must be reported
[11].
To check the interference of missing values for maternal
plasma viral load, 3 logistic regression models were performed.
Interruption of ART in the first trimester was associated with
an adjusted OR of 10.33 (95% CI, 2.02–52.91; ), andPp .005
interruption of ART in the third trimester was associated with
an adjusted OR of 46.86 (95% CI, 4.28–512.64; ) inPp .002
the whole cohort, with the inclusion of maternal viral load as
a category with missing values. When only cases with known
maternal viral load were included, the adjusted OR for inter-
ruption of ART in the first trimester was 11.45 (95% CI, 1.58–
83.08; ) and in the third trimester was 24.33 (95% CI,Pp .016
0.77–765.92; ). When maternal viral load was ex-Pp .070
cluded, the adjusted OR for interruption of ART in the first
trimester was 8.32 (95% CI, 1.88–36.90; ) and in thePp .005
third trimester was 40.52 (95% CI, 4.24–387.64; ) inPp .001
the whole cohort.
Finally, a logistic regression model on a subgroup (np
) of mother-child pairs with both known plasma viral load538
and known CD4+ cell count was performed, including these
factors as continuous variables. Treatment interruption in the
first trimester was associated with an adjusted OR of 10.70
(95% CI, 1.48–77.18), and treatment interruption in the third
trimester was associated with an adjusted OR of 30.38 (95%
CI, 0.98–941.66). Plasma viral load was associated with an ad-
justed OR of 2.50 (95% CI, 1.27–4.91), and CD4+ cell count
was associated with an adjusted OR of 1.87 (95% CI, 0.07–
53.26). Thus, treatment interruption in the first trimester was
associated with a 10-fold increased risk of MTCT, whereas a
plasma viral load increase of 1 log10 copies/mL doubled the risk
of MTCT.
DISCUSSION
To our knowledge, this is the first study to reveal that discon-
tinuing ART during pregnancy increases the rate of MTCT of
HIV-1, either when ART is stopped in the first trimester and
subsequently restarted, or when it is interrupted in the third
trimester. The last finding was partly expected, because dis-
continuation of treatment could lead to a viremic rebound [12,
13] and because a higher viral load near the time of delivery
increases the risk of MTCT, as we and others have clearly shown
[14, 15]. The incremental risk of MTCT associated with treat-
ment interruption is high among all treated women, even
among HAART-treated women, maybe because the viremic re-
bound is stronger if the virological potency of therapy is higher.
Therefore, our findings confirm the recommendation that preg-
nant women infected with HIV-1 who receive ART should
continue treatment after the first trimester, particularly at the
end of pregnancy [7]. More interestingly, we found that inter-
ruption of ART early in pregnancy increased the rate of MTCT
both in the whole cohort and among children born to HAART-
treated women. To our knowledge, no other large study has
investigated this issue. Of note, in our cohort, temporary ART
discontinuation early in pregnancy is more frequent in women
receiving HAART, probably because of the fear of drug toxicity
in the embryo. However, temporary discontinuation led to a
10-fold increase in the rate of MTCT, overcoming all other risk
factors, except for the independent factor of high plasma viral
RNA load at delivery. When viral load increased by 1 log10
copies/mL, the risk of MTCT was, indeed, more than doubled.
A small proportion of HAART-treated women may have high
plasma viral loads because of poor compliance or mutations
associated with viral resistance [16]. Nevertheless, we found no
difference in predelivery plasma viral load between mothers
who temporarily discontinued therapy and mothers who did
not. It might be speculated that a transient viral load increase,
occurring close to the time of ART interruption, favors HIV-
1 transmission.
We also investigated whether a lower antiretroviral potency
of the regimen administered after suspension could lead to
higher risk of MTCT, but the proportions of nevirapine-based
or PI-based regimens were similar before and after interruption.
However, it is possible that virological failure occurred more
frequently because of nevirapine-resistance mutations [17] in
those women who discontinued and restarted the same nevi-
rapine-based regimen. Viral load at delivery was similar in the
women treated with a PI-based regimen and in those treated
with a nonnucleoside reverse-transcriptase inhibitor–based reg-
imen in both the whole cohort and in those who had therapy
interrupted. In addition, we found a trend toward higher viral
loads in women treated with a PI-based regimen than in those
treated with an nonnucleoside reverse-transcriptase inhibitor–
based regimen, as recently was reported by the European Col-
laborative Study [18]. It is possible that women with lower
baseline viral loads (before or at the beginning of pregnancy)
are more often treated with nonnucleoside reverse-transcriptase
inhibitor–based regimens, or the pharmacokinetic peculiarities
of ART in pregnancy may be involved [18].
Because our data are from a large pediatric cohort, a limi-
tation in our analyses is that some detailed information on the
mothers was lacking. First of all, maternal viral load at delivery
was unknown for ∼30% of mother-child pairs. However, when
mother-child pairs were compared according to whether ma-
ternal viral load was known or unknown, exactly the same
MTCT rate was found. As an additional check, 3 different
logistic regression models were performed, but the main role
of ART interruption in pregnancy was constantly confirmed.
Another critical point is the unavailability in our database of
information on the reasons for ART discontinuation during
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pregnancy. Therapy could be discontinued for several reasons:
the development of virological failure or resistance mutations,
the occurrence of adverse effects, or the desire to avoid fetal
exposure during the first trimester. On the other hand, ART
interruption was not homogeneously distributed during the
whole pregnancy, peaking at 6 and 32 weeks. We think that
avoidance of fetal exposure during the first trimester and in-
tolerance of treatment are the most probable reasons for ART
discontinuation, and if so, it would be unlikely that women
who had ART suspended were a priori at higher risk of MTCT
because of virological failure or resistance mutations. Unfor-
tunately, we had no data on maternal viral load during ges-
tation. Moreover, we could not assess whether infected children
born to mothers who had ART interrupted acquired the in-
fection in utero or perinatally [19], because we do not system-
atically measure HIV-1 RNA or DNA load during the first 24–
48 h of life.
We investigated all interactions between variables that we
thought were biologically convincing. Other important factors
might be compliance to ART and genotype resistance in the
mothers, but these data were lacking in our database. Finally,
the very low number of infected children in the whole cohort
and, consequently, the wide 95% CIs found, are additional
caveats. Additional studies, prospectively performed using large
cohorts of mother-child pairs starting from the beginning of
gestation, may confirm our findings. It may be surprising that
we found no relationship between intrapartum and neonatal
therapy and the rate of MTCT, but the numbers of mother-
child pairs who were not receiving intrapartum and neonatal
prophylaxis were too small to draw any conclusion. Moreover,
we found no differences according to trimester at start of ART,
even if a higher proportion of HAART-treated women had a
detectable viral load at delivery when treatment was used during
the third trimester, compared with the first or second trimester.
This finding supports recently revised guidelines [7] that rec-
ommend that, in women who do not require ART for their
own health, ART for MTCT prophylaxis may be started during
the second trimester, preferably with a 3-drug regimen.
The main finding of our study is that no other factors but
the discontinuation of ART and high maternal viral load at
delivery are associated with an increased risk of MTCT. Thus,
although concerns about potential toxicity in the fetus need to
be completely clarified, counseling on the temporary discon-
tinuation of ART in the first trimester should consider both
the need for maternal health [7] and the increased risk of HIV-
1 transmission to the offspring. We believe that our findings
may be useful for physicians who care for women infected with
HIV-1 and for specialists who determine guidelines.
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